KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA— First and Only Submental Contouring Injectable Drug

Industry News

Kythera Biopharmaceuticals, Inc., a biotechnology company based in Westlake Village, CA, announced that the U.S. Food and Drug Administration (FDA) has approved KybellaTM, a treatment for adults with moderate-to-severe fat below the chin, known as submental fat or double-chin. Kybella is a formulation of deoxycholic acid, a secondary bile acid made by the gut bacteria in human that aids the breakdown and absorption of dietary fat.  When Kybella is injected into subcutaneous fat, it destroys the fat cells preventing fat accumulating and resulting in reduction of submenal fullness.  Kybella is the first and only approved non-surgical treatment for reduction of submental fat, a common yet under-treated aesthetic condition.

 

Related Link:

http://www.mykybella.com/wp-content/uploads/2015/04/KYTHERA-FDA-Approval-Press-Release-4.29.15-FINAL_.pdf
http://www.kythera.com/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm

Subscribe to WXPress

Receive our newsletter and information on upcoming events.